Literature DB >> 7678188

Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function.

K K Lee1, J M Langrehr, M J Stangl, B Banner, T K Lee, A Müller, W H Schraut.   

Abstract

Acute rejection episodes often complicate clinical small bowel transplantation, which prompted us to investigate whether such episodes can be reversed and the intestinal graft salvaged. Inbred Lewis rats that received fully allogeneic Brown-Norway small bowel allografts were treated with cyclosporin A (10 mg/kg) for 5 days, and the drug was then discontinued. Clinical and histologic signs of acute rejection developed, and the animals were subsequently treated with FK 506 (2 mg/kg) on days 14, 16, and 18. Survival was significantly prolonged (201.7 +/- 46.8 days) when compared with animals that were not administered FK 506 (16.5 +/- 0.8 days) or allograft recipients that received no immunosuppressive therapy (10.8 +/- 0.7 days). The histologic changes and functional impairment due to rejection that were observed prior to the start of the FK 506-therapy were reversed. However, biopsy specimens of all animals exhibited features of chronic rejection. This study provides evidence that acute rejection of intestinal allografts can be successfully treated with a short course of FK 506.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678188     DOI: 10.1016/s0002-9610(05)80416-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  EGF and TGF-beta1 gene expression in chronically rejecting small bowel transplants.

Authors:  E A Kouwenhoven; A N Stein-Oakley; P Jablonski; R W de Bruin; N M Thomson
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

2.  Immunogenicity of parathyroid allografts in the rat: immunosuppressive dosages effective in passenger leukocyte-rich small bowel transplants are not effective in parathyroid gland transplants with few passenger leukocytes.

Authors:  S Timm; C Otto; D Begrich; V Moskalenko; W Hamelmann; K Ulrichs; A Thiede; W Timmermann
Journal:  Langenbecks Arch Surg       Date:  2003-12-05       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.